{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:17:57Z","timestamp":1792451877953,"version":"4.5.0"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.lfs.2023.122003","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T21:47:51Z","timestamp":1691185671000},"page":"122003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Role of CRISPR\/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies"],"prefix":"10.1016","volume":"330","author":[{"given":"Pooja","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vancha","family":"Harish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharfuddin","family":"Mohd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devesh","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramanjireddy","family":"Tatiparthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Harshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukriti","family":"Vishwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Sutrapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2023.122003_bb0005","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2023.122003_bb0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Aartsma-Rus","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lfs.2023.122003_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.lfs.2023.122003_bb0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nmd.2017.03.011","article-title":"Duchenne muscular dystrophy in a female with compound heterozygous contiguous exon deletions","volume":"27","author":"Takeshita","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.lfs.2023.122003_bb0025","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.lfs.2023.122003_bb0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.lfs.2023.122003_bb0035","series-title":"StatPearls [Internet]","article-title":"Duchenne muscular dystrophy","author":"Venugopal","year":"2023"},{"issue":"1981","key":"10.1016\/j.lfs.2023.122003_bb0040","first-page":"1055","article-title":"Familial studies of intelligence: a review","volume":"212","author":"Bouchard","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.lfs.2023.122003_bb0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1469-8749.1981.tb02039.x","article-title":"Intellect and behaviour in Duchenne muscular dystrophy","volume":"23","author":"Leibowitz","year":"1981","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.lfs.2023.122003_bb0050","unstructured":"The history of a genetic disease: Duchenne muscular dystrophy or Meryon's ... - Alan E. H. Emery, Marcia L. H. Emery - Google Books, (n.d.). https:\/\/books.google.co.in\/books?hl=en&lr=&id=gf1BLLrCuwMC&oi=fnd&pg=PR7&dq=duchenne+muscular+dystrophy+history&ots=dYzMcF4DnC&sig=9-nedhgQ4I-zJzFCM5PQtzjuHCs&redir_esc=y#v=onepage&q=duchenne%20muscular%20dystrophy%20history&f=false (accessed April 9, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0339-7","article-title":"Recent advances in the CRISPR genome editing tool set","volume":"51","author":"Bin Moon","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.lfs.2023.122003_bb0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","article-title":"CRISPR correction of duchenne muscular dystrophy","volume":"70","author":"Min","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.lfs.2023.122003_bb0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1152\/physrev.00028.2001","article-title":"Function and genetics of dystrophin and dystrophin-related proteins in muscle","volume":"82","author":"Blake","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.lfs.2023.122003_bb0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0959-437X(03)00048-0","article-title":"Muscular dystrophies: genes to pathogenesis","volume":"13","author":"Dalkilic","year":"2003","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.lfs.2023.122003_bb0075","doi-asserted-by":"crossref","first-page":"12575","DOI":"10.1038\/s41598-017-12981-5","article-title":"Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy","volume":"7","author":"Doorenweerd","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122003_bb0080","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-0333I","article-title":"Cardiac management of the patient with Duchenne muscular dystrophy","volume":"142","author":"Buddhe","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.lfs.2023.122003_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s13395-017-0124-z","article-title":"The golden retriever model of Duchenne muscular dystrophy","volume":"7","author":"Kornegay","year":"2017","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.lfs.2023.122003_bb0090","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1083\/jcb.117.5.997","article-title":"Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle","volume":"117","author":"Porter","year":"1992","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.lfs.2023.122003_bb0095","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1242\/jcs.00003","article-title":"Calponin homology domains at a glance","volume":"115","author":"Korenbaum","year":"2002","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.lfs.2023.122003_bb0100","series-title":"Spectrin, \u03b1-Actinin, and Dystrophin","first-page":"203","author":"Broderick","year":"2005"},{"key":"10.1016\/j.lfs.2023.122003_bb0105","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1016\/S0021-9258(19)39599-7","article-title":"Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility","volume":"265","author":"Koenig","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2023.122003_bb0110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.molmed.2016.04.002","article-title":"Satellite cells in muscular dystrophy \u2013 lost in polarity","volume":"22","author":"Chang","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.lfs.2023.122003_bb0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10741-009-9156-8","article-title":"Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics","volume":"15","author":"Fayssoil","year":"2010","journal-title":"Heart Fail. Rev."},{"issue":"3","key":"10.1016\/j.lfs.2023.122003_bb0120","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The dystrophin complex: structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"issue":"4","key":"10.1016\/j.lfs.2023.122003_bb0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2213-2600(21)00581-6","article-title":"Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges","volume":"10","author":"Birnkrant","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"10","key":"10.1016\/j.lfs.2023.122003_bb0130","article-title":"Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy","volume":"10","author":"Bourke","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.lfs.2023.122003_bb0135","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.001782","article-title":"Cardiac dysfunction in Duchenne muscular dystrophy is less frequent in patients with mutations in the dystrophin Dp116 coding region than in other regions","volume":"11","author":"Yamamoto","year":"2018","journal-title":"Circ. Genom Precis. Med."},{"key":"10.1016\/j.lfs.2023.122003_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/children8100835","article-title":"Characteristics of clinical trial participants with Duchenne muscular dystrophy: data from the muscular dystrophy surveillance, tracking, and research network (MD STARnet)","volume":"8","author":"Mathews","year":"2021","journal-title":"Children"},{"key":"10.1016\/j.lfs.2023.122003_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004347","article-title":"Clinical heterogeneity of Duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up","volume":"4","author":"Desguerre","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2023.122003_bb0150","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/jmg.30.9.737","article-title":"Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients","volume":"30","author":"Nicholson","year":"1993","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.lfs.2023.122003_bb0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1017\/S0012162205000496","article-title":"Association between intellectual functioning and age in children and young adults with Duchenne muscular dystrophy: further results from a meta-analysis","volume":"47","author":"Cotton","year":"2005","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.lfs.2023.122003_bb0160","first-page":"497","article-title":"Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients","volume":"43","author":"Cotton","year":"2001","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.lfs.2023.122003_bb0165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/adc.44.234.221","article-title":"Intelligence and the gene for Duchenne muscular dystrophy","volume":"44","author":"Jane Prosser","year":"1969","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.lfs.2023.122003_bb0170","series-title":"Cognitive and Psychological Profile of Males With Becker Muscular Dystrophy","first-page":"155","volume":"23","author":"Young","year":"2007"},{"key":"10.1016\/j.lfs.2023.122003_bb0175","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1006\/mgme.1998.2763","article-title":"Redefinition of dystrophin isoform distribution in mouse tissue by RT-PCR implies role in nonmuscle manifestations of Duchenne muscular dystrophy","volume":"65","author":"Tokarz","year":"1998","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.lfs.2023.122003_bb0180","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jmedgenet-2015-103387","article-title":"The importance of genetic diagnosis for Duchenne muscular dystrophy","volume":"53","author":"Aartsma-Rus","year":"2016","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.lfs.2023.122003_bb0185","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2014.14604","article-title":"Clinical exome sequencing for genetic identification of rare Mendelian disorders","volume":"312","author":"Lee","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2023.122003_bb0190","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.1992.03480190051030","article-title":"Diagnosis of Duchenne and Becker muscular dystrophies by polymerase chain reaction. A multicenter study","volume":"267","author":"JS","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2023.122003_bb0195","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/genes11080837","article-title":"Therapeutic strategies for duchenne muscular dystrophy: an update","volume":"11","author":"Sun","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.lfs.2023.122003_bb0200","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/sj.ejhg.5201465","article-title":"Deletion and duplication screening in the DMD gene using MLPA","volume":"13","author":"Lalic","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.lfs.2023.122003_bb0205","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.nmd.2010.04.005","article-title":"Best practice guidelines on molecular diagnostics in Duchenne\/Becker muscular dystrophies","volume":"20","author":"Abbs","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.lfs.2023.122003_bb0210","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrg.2017.116","article-title":"Paediatric genomics: diagnosing rare disease in children","volume":"19","author":"Wright","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.lfs.2023.122003_bb0215","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jmoldx.2016.05.003","article-title":"Implementation of a reliable next-generation sequencing strategy for molecular diagnosis of dystrophinopathies","volume":"18","author":"Alame","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.lfs.2023.122003_bb0220","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/jmedgenet-2011-100133","article-title":"Genetic diagnosis of Duchenne and Becker muscular dystrophy using next-generation sequencing technology: comprehensive mutational search in a single platform","volume":"48","author":"Lim","year":"2011","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.lfs.2023.122003_bb0225","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cca.2019.01.014","article-title":"Molecular genetic testing and diagnosis strategies for dystrophinopathies in the era of next generation sequencing","volume":"491","author":"Zhang","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.lfs.2023.122003_bb0230","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0140-6736(85)91325-X","article-title":"prenatal diagnosis and carrier detection of duchenne muscular dystrophy with closely linked RFLPs","volume":"325","author":"Bakker","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2023.122003_bb0235","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/gim.2014.207","article-title":"Haplotype-based approach for noninvasive prenatal tests of Duchenne muscular dystrophy using cell-free fetal DNA in maternal plasma","volume":"17","author":"Xu","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.lfs.2023.122003_bb0240","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.lfs.2023.122003_bb0245","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.lfs.2023.122003_bb0250","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2023.122003_bb0255","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nature10886","article-title":"RNA-guided genetic silencing systems in bacteria and archaea","volume":"482","author":"Wiedenheft","year":"2012","journal-title":"Nature"},{"issue":"2013","key":"10.1016\/j.lfs.2023.122003_bb0260","first-page":"823","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.lfs.2023.122003_bb0265","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lfs.2023.122003_bb0270","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-genet-110410-132430","article-title":"CRISPR-Cas Systems in Bacteria and Archaea: versatile small RNAs for adaptive defense and regulation","volume":"45","author":"Bhaya","year":"2011","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.lfs.2023.122003_bb0275","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2023.122003_bb0280","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.mib.2011.03.005","article-title":"CRISPR-based adaptive immune systems","volume":"14","author":"Terns","year":"2011","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.lfs.2023.122003_bb0285","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000088674","article-title":"Epidemiological study of muscular disorders in Assiut, Egypt","volume":"25","author":"El-Tallawy","year":"2005","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.lfs.2023.122003_bb0290","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.lfs.2023.122003_bb0295","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature13011","article-title":"DNA interrogation by the CRISPR RNA-guided endonuclease Cas9","volume":"507","author":"Sternberg","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2023.122003_bb0300","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1021\/acs.biochem.1c00354","article-title":"Coordinated actions of Cas9 HNH and RuvC nuclease domains are regulated by the bridge Helix and the target DNA sequence","volume":"60","author":"Babu","year":"2021","journal-title":"Biochemistry"},{"key":"10.1016\/j.lfs.2023.122003_bb0305","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1101\/gr.162339.113","article-title":"Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases","volume":"24","author":"Cho","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.lfs.2023.122003_bb0310","first-page":"816","article-title":"A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science (1979)"},{"key":"10.1016\/j.lfs.2023.122003_bb0315","doi-asserted-by":"crossref","first-page":"21312","DOI":"10.1074\/jbc.M114.564625","article-title":"Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)\/Cas9 nuclease system in mammalian cells*","volume":"289","author":"Canver","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2023.122003_bb0320","unstructured":"CRISPR\/Cas9 | CRISPR, (n.d.). https:\/\/crisprtx.com\/gene-editing\/crispr-cas9 (accessed July 4, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.699597","article-title":"The potential of CRISPR\/Cas9 gene editing as a treatment strategy for inherited diseases","volume":"9","author":"Abdelnour","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.lfs.2023.122003_bb0330","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.lfs.2023.122003_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2023.122003_bb0340","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"Hsu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lfs.2023.122003_bb0345","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nmeth.3733","article-title":"Editing the epigenome: technologies for programmable transcription and epigenetic modulation","volume":"13","author":"Thakore","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.lfs.2023.122003_bb0350","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/j.ymthe.2021.04.002","article-title":"CRISPR technologies for the treatment of Duchenne muscular dystrophy","volume":"29","author":"Choi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2023.122003_bb0355","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s13311-022-01197-9","article-title":"CRISPR-Cas9 gene therapy for Duchenne muscular dystrophy","volume":"19","author":"Happi Mbakam","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.lfs.2023.122003_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms7244","article-title":"Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy","volume":"6","author":"Ousterout","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2023.122003_bb0365","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aap9004","article-title":"Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing","volume":"4","author":"Long","year":"2018","journal-title":"Sci. Adv."},{"key":"10.1016\/j.lfs.2023.122003_bb0370","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ymthe.2018.08.010","article-title":"CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in vitro and in vivo","volume":"26","author":"Duch\u00eane","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2023.122003_bb0375","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","article-title":"Exon skipping therapy for Duchenne muscular dystrophy","volume":"87","author":"Kole","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.lfs.2023.122003_bb0380","article-title":"Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy","volume":"15","author":"L\u00f3pez","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2023.122003_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.147358","article-title":"New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy","volume":"867","author":"Eslahi","year":"2023","journal-title":"Gene"},{"issue":"14","key":"10.1016\/j.lfs.2023.122003_bb0390","article-title":"Duchenne muscular dystrophy: disease mechanism and therapeutic strategies","author":"Bez Batti Angulski","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.lfs.2023.122003_bb0395","first-page":"1","article-title":"Methods favoring homology-directed repair choice in response to CRISPR\/Cas9 induced-double strand breaks","volume":"21","author":"Yang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2023.122003_bb0400","unstructured":"Non-Homologous End Joining, Homology-Directed Repair, (n.d.). https:\/\/www.beckman.com\/support\/faq\/research\/nhej-hdr-difference (accessed July 4, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0405","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ddtec.2018.08.001","article-title":"CRISPR\/Cas9 genome engineering in hematopoietic cells","volume":"28","author":"S\u00fcr\u00fcn","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.lfs.2023.122003_bb0410","series-title":"Microinjection and Micromanipulation: A Historical Perspective","first-page":"1","author":"Xu","year":"2019"},{"key":"10.1016\/j.lfs.2023.122003_bb0415","doi-asserted-by":"crossref","first-page":"16304","DOI":"10.1038\/s41598-018-34601-6","article-title":"TRIAMF: a new method for delivery of Cas9 ribonucleoprotein complex to human hematopoietic stem cells","volume":"8","author":"Yen","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122003_bb0420","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.cell.2015.03.028","article-title":"Efficient intracellular delivery of native proteins","volume":"161","author":"D\u2019Astolfo","year":"2015","journal-title":"Cell"},{"issue":"2016","key":"10.1016\/j.lfs.2023.122003_bb0425","first-page":"407","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.lfs.2023.122003_bb0430","article-title":"Viral vectors for the in vivo delivery of CRISPR components: advances and challenges","volume":"10","author":"Asmamaw","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.lfs.2023.122003_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/biom10060839","article-title":"Recent advances in CRISPR\/Cas9 delivery strategies","volume":"10","author":"Yip","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.lfs.2023.122003_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.673286","article-title":"Nanoparticle delivery of CRISPR\/Cas9 for genome editing","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.lfs.2023.122003_bb0445","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41434-021-00282-6","article-title":"Non-viral delivery of CRISPR\u2013Cas9 complexes for targeted gene editing via a polymer delivery system","volume":"29","author":"O\u2019Keeffe Ahern","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.lfs.2023.122003_bb0450","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nbt.3149","article-title":"A split-Cas9 architecture for inducible genome editing and transcription modulation","volume":"33","author":"Zetsche","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lfs.2023.122003_bb0455","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2015.087","article-title":"Adenovirus-mediated somatic genome editing of Pten by CRISPR\/Cas9 in mouse liver in spite of Cas9-specific immune responses","volume":"26","author":"Wang","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.lfs.2023.122003_bb0460","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cell.2006.07.025","article-title":"Reversible, and tunable method to regulate protein function in living cells using synthetic small molecules","volume":"126","author":"Banaszynski","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2023.122003_bb0465","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ymthe.2018.10.008","article-title":"Optimization of CRISPR\/Cas9 delivery to human hematopoietic stem and progenitor cells for therapeutic genomic rearrangements","volume":"27","author":"Lattanzi","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2023.122003_bb0470","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/j.celrep.2017.08.075","article-title":"The self-inactivating KamiCas9 system for the editing of CNS disease genes","volume":"20","author":"Merienne","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.lfs.2023.122003_bb0475","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5\u2013human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2023.122003_bb0480","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials."},{"key":"10.1016\/j.lfs.2023.122003_bb0485","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.895713","article-title":"Viral vectors for the in vivo delivery of CRISPR components: advances and challenges","volume":"10","author":"Asmamaw Mengstie","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.lfs.2023.122003_bb0490","doi-asserted-by":"crossref","DOI":"10.3390\/v11010028","article-title":"Viral delivery systems for CRISPR","volume":"11","author":"Xu","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.lfs.2023.122003_bb0495","doi-asserted-by":"crossref","DOI":"10.1002\/marc.201800068","article-title":"Cationic polymer-mediated CRISPR\/Cas9 plasmid delivery for genome editing","volume":"40","author":"Zhang","year":"2019","journal-title":"Macromol. Rapid Commun."},{"key":"10.1016\/j.lfs.2023.122003_bb0500","doi-asserted-by":"crossref","first-page":"12029","DOI":"10.1002\/anie.201506030","article-title":"Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing","volume":"54","author":"Sun","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.lfs.2023.122003_bb0505","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jconrel.2004.07.027","article-title":"Enhanced transfection efficiency of PAMAM dendrimer by surface modification with L-arginine","volume":"99","author":"Choi","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2023.122003_bb0510","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/jacs.7b11754","article-title":"Endosomal escape and delivery of CRISPR\/Cas9 genome editing machinery enabled by nanoscale zeolitic imidazolate framework","volume":"140","author":"Alsaiari","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.lfs.2023.122003_bb0515","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.lfs.2023.122003_bb0520","series-title":"Targeted Genome Editing in Potato Protoplast Via Optical Delivery of CRISPR\/Cas9 Ribonucleoproteins","first-page":"76","author":"Londenberg","year":"2020"},{"key":"10.1016\/j.lfs.2023.122003_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201700175","article-title":"Genome editing for cancer therapy: delivery of Cas9 protein\/sgRNA plasmid via a gold nanocluster\/lipid core\u2013shell nanocarrier","volume":"4","author":"Wang","year":"2017","journal-title":"Adv. Sci."},{"key":"10.1016\/j.lfs.2023.122003_bb0530","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1182\/blood-2021-150924","article-title":"Efficient nanoparticle-mediated delivery of gene editing reagents into human hematopoietic stem and progenitor cells","volume":"138","author":"El Kharrag","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2023.122003_bb0535","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.lfs.2023.122003_bb0540","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/09205063.2022.2121592","article-title":"Lipid-based nanocarrier mediated CRISPR\/Cas9 delivery for cancer therapy","volume":"34","author":"Aziz","year":"2023","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.lfs.2023.122003_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010213","article-title":"Impact of formulation conditions on lipid nanoparticle characteristics and functional delivery of CRISPR RNP for gene knock-out and correction","volume":"14","author":"Walther","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2023.122003_bb0550","doi-asserted-by":"crossref","DOI":"10.1038\/am.2017.185","article-title":"Lipid nanoparticle-mediated efficient delivery of CRISPR\/Cas9 for tumor therapy","volume":"9","author":"Zhang","year":"2017","journal-title":"NPG Asia Mater."},{"key":"10.1016\/j.lfs.2023.122003_bb0555","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-1-4939-9740-4_13","article-title":"Zygote electroporation for CRISPR\/Cas9 delivery to generate genetically modified mice","volume":"2050","author":"Takemoto","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.lfs.2023.122003_bb0560","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16328-y","article-title":"Generation of gene-edited rats by delivery of CRISPR\/Cas9 protein and donor DNA into intact zygotes using electroporation","volume":"7","author":"Remy","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122003_bb0565","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/978-1-0716-1979-7_24","article-title":"Reprogramming mouse oviduct epithelial cells using in vivo electroporation and CRISPR\/Cas9-mediated genetic manipulation","volume":"2429","author":"Ford","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.lfs.2023.122003_bb0570","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1109\/TBME.2022.3149530","article-title":"Knock-in of a large reporter gene via the high-throughput microinjection of the CRISPR\/Cas9 system","volume":"69","author":"Chen","year":"2022","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"10.1016\/j.lfs.2023.122003_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.973326","article-title":"Delivering the CRISPR\/Cas9 system for engineering gene therapies: recent cargo and delivery approaches for clinical translation","volume":"10","author":"Foley","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.lfs.2023.122003_bb0580","doi-asserted-by":"crossref","DOI":"10.1038\/srep16031","article-title":"Controlled delivery of \u03b2-globin-targeting TALENs and CRISPR\/Cas9 into mammalian cells for genome editing using microinjection","volume":"5","author":"Cottle","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122003_bb0585","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1609","article-title":"Strategies for nonviral nanoparticle-based delivery of CRISPR\/Cas9 therapeutics","volume":"12","author":"Chen","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.lfs.2023.122003_bb0590","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s10616-018-0252-2","article-title":"Establishing a dual knock-out cell line by lentivirus based combined CRISPR\/Cas9 and Loxp\/Cre system","volume":"70","author":"Li","year":"2018","journal-title":"Cytotechnology"},{"issue":"7","key":"10.1016\/j.lfs.2023.122003_bb0595","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3390\/v13071288","article-title":"Lentiviral vectors for delivery of gene-editing systems based on CRISPR\/Cas: current state and perspectives","volume":"13","author":"Dong","year":"2021","journal-title":"Viruses."},{"key":"10.1016\/j.lfs.2023.122003_bb0600","doi-asserted-by":"crossref","DOI":"10.1007\/s13205-019-1966-3","article-title":"Efficient knock-in at the chicken ovalbumin locus using adenovirus as a CRISPR\/Cas9 delivery system","volume":"9","author":"Qin","year":"2019","journal-title":"3 Biotech"},{"key":"10.1016\/j.lfs.2023.122003_bb0605","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2144\/btn-2022-0051","article-title":"Adenovirus vector system: construction, history and therapeutic applications","volume":"73","author":"Syyam","year":"2022","journal-title":"Biotechniques"},{"key":"10.1016\/j.lfs.2023.122003_bb0610","doi-asserted-by":"crossref","first-page":"17113","DOI":"10.1038\/s41598-017-17180-w","article-title":"CRISPR\/Cas9 delivery with one single adenoviral vector devoid of all viral genes","volume":"7","author":"Ehrke-Schulz","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122003_bb0615","doi-asserted-by":"crossref","DOI":"10.1111\/febs.16771","article-title":"Therapeutic applications of CRISPR\/Cas9 gene editing technology for the treatment of ocular diseases","author":"Sundaresan","year":"2023","journal-title":"FEBS J."},{"key":"10.1016\/j.lfs.2023.122003_bb0620","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091842","article-title":"Non-viral delivery of CRISPR\/Cas cargo to the retina using nanoparticles: current possibilities, challenges, and limitations","volume":"14","author":"Salman","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lfs.2023.122003_bb0625","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202104979","article-title":"Molecular signature of astrocytes for gene delivery by the synthetic adeno-associated viral vector rAAV9P1","volume":"9","author":"Bauer","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.lfs.2023.122003_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1566523221666211006120355","article-title":"CRISPR systems suitable for single AAV vector delivery","volume":"22","author":"Stevanovic","year":"2022","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.lfs.2023.122003_bb0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/1369682","article-title":"Era of genomic medicine: a narrative review on CRISPR technology as a potential therapeutic tool for human diseases","volume":"2019","author":"Kotagama","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.lfs.2023.122003_bb0640","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","article-title":"Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges","volume":"342","author":"Taha","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.lfs.2023.122003_bb0645","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/thno.47007","article-title":"Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.lfs.2023.122003_bb0650","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.apsb.2021.05.020","article-title":"In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges","volume":"11","author":"Behr","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.lfs.2023.122003_bb0655","unstructured":"A. Ali, S. Aslam, S. Tabasum, R. Aslam, Overview of delivery of CRISPR\/Cas systems, its types and role in genome editing and immunotherapy, J. RNA Genomics 17 (n.d.). doi:10.35841\/2591-7781.17.3.665-672."},{"key":"10.1016\/j.lfs.2023.122003_bb0660","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.3390\/ijms22116072","article-title":"CRISPR\/Cas9: principle, applications, and delivery through extracellular vesicles","volume":"22","author":"Horodecka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2023.122003_bb0665","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031832","article-title":"CRISPR therapeutics for Duchenne muscular dystrophy","volume":"23","author":"Erkut","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.lfs.2023.122003_bb0670","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/jcm10040820","article-title":"Innovative therapeutic approaches for duchenne muscular dystrophy","volume":"10","author":"Fortunato","year":"2021","journal-title":"J. Clin. Med."},{"issue":"15","key":"10.1016\/j.lfs.2023.122003_bb0675","article-title":"Microfluidic and nanofluidic intracellular delivery","volume":"8","author":"Hur","year":"2021","journal-title":"Adv. Sci. (Weinh)"},{"issue":"6","key":"10.1016\/j.lfs.2023.122003_bb0680","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2023.122003_bb0685","unstructured":"Research - Duchenne Muscular Dystrophy (DMD) - Diseases | Muscular Dystrophy Association, (n.d.). https:\/\/www.mda.org\/disease\/duchenne-muscular-dystrophy\/research (accessed April 6, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0690","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.cell.2017.04.005","article-title":"CRISPR-based technologies for the manipulation of eukaryotic genomes","volume":"169","author":"Komor","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2023.122003_bb0695","article-title":"Challenges and prospects of CRISPR\/Cas9 gene editing for treating Duchenne muscular dystrophy","volume":"271","author":"Bulaklak","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2023.122003_bb0700","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-018-04252-2","article-title":"The CRISPR tool kit for genome editing and beyond","volume":"9","author":"Adli","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2023.122003_bb0705","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2023.122003_bb0710","series-title":"Challenges and Prospects of CRISPR\/Cas9 Gene Editing for Treating Duchenne Muscular Dystrophy","first-page":"271","author":"Bulaklak","year":"2021"},{"key":"10.1016\/j.lfs.2023.122003_bb0715","first-page":"212","article-title":"Non-viral delivery of genome- editing nucleases for gene therapy","volume":"27","author":"Wang","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.lfs.2023.122003_bb0720","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.lfs.2023.122003_bb0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01487-4","article-title":"Strategies to overcome the main challenges of the use of CRISPR\/Cas9 as a replacement for cancer therapy","volume":"21","author":"Rasul","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.lfs.2023.122003_bb0730","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/genes11101113","article-title":"Delivery approaches for therapeutic genome editing and challenges","volume":"11","author":"Ates","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.lfs.2023.122003_bb0735","series-title":"Advances in CRISPR Delivery Methods: Perspectives and Challenges, Https:\/\/Home.Liebertpub.Com\/Crispr","first-page":"660","volume":"5","author":"Demirci","year":"2022"},{"key":"10.1016\/j.lfs.2023.122003_bb0740","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fgeed.2020.602970","article-title":"Methodologies and challenges for CRISPR\/Cas9 mediated genome editing of the mammalian brain","volume":"2","author":"Nishizono","year":"2020","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.lfs.2023.122003_bb0745","unstructured":"New Approach More than Doubles Stem Cell Editing Efficiency, Researchers Report Penn State University, (n.d.). https:\/\/www.psu.edu\/news\/engineering\/story\/new-approach-more-doubles-stem-cell-editing-efficiency-researchers-report\/ (accessed April 6, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0750","first-page":"1","article-title":"Enhanced genome editing efficiency of CRISPR PLUS: Cas9 chimeric fusion proteins","volume":"11","author":"Park","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2023.122003_bb0755","unstructured":"Verification of CRISPR gene editing efficiency | Thermo Fisher Scientific - IN, (n.d.). https:\/\/www.thermofisher.com\/in\/en\/home\/life-science\/genome-editing\/genome-editing-learning-center\/genome-editing-resource-library\/crispr-validated-protocols\/verification-crispr-gene-editing-efficiency.html (accessed April 6, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0760","unstructured":"zhttps:\/\/insights.som.yale.edu\/insights\/is-crispr-worth-the-risk (accessed April 7, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0765","article-title":"The gene editor CRISPR won\u2019t fully fix sick people anytime soon. Here\u2019s why","volume":"1979","author":"Kaiser","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.lfs.2023.122003_bb0770","unstructured":"CRISPR gene editing carries a potential risk, study finds - Boston Children's Answers, (n.d.). https:\/\/answers.childrenshospital.org\/crispr-gene-editing\/ (accessed April 7, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0775","unstructured":"Lab tests show risks of using CRISPR gene editing on embryos - STAT, (n.d.). https:\/\/www.statnews.com\/2020\/10\/29\/lab-tests-show-risks-of-using-crispr-gene-editing-on-embryos\/ (accessed April 7, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0780","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","article-title":"CRISPR-Cas9: a preclinical and clinical perspective for the treatment of human diseases","volume":"29","author":"Sharma","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2023.122003_bb0785","unstructured":"News: CRISPR approaches to duchenne muscular dystrophy - CRISPR medicine, (n.d.). https:\/\/crisprmedicinenews.com\/news\/crispr-approaches-to-duchenne-muscular-dystrophy\/ (accessed April 7, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0790","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/cr.2016.28","article-title":"Duchenne muscular dystrophy: CRISPR\/Cas9 treatment","volume":"26","author":"Mendell","year":"2016","journal-title":"Cell Res."},{"key":"10.1016\/j.lfs.2023.122003_bb0795","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3389\/fbioe.2022.833833","article-title":"A decade of progress in gene targeted therapeutic strategies in Duchenne muscular dystrophy: a systematic review","volume":"10","author":"Chung Liang","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.lfs.2023.122003_bb0800","article-title":"CRISPR-based therapeutic gene editing for Duchenne muscular dystrophy: advances, challenges and perspectives","volume":"11","author":"Chen","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2023.122003_bb0805","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41434-021-00222-4","article-title":"Genome editing for Duchenne muscular dystrophy: a glimpse of the future?","volume":"28","author":"Kupatt","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.lfs.2023.122003_bb0810","unstructured":"Muscular Dystrophy Clinical Trials | Find a Clinical Trial Near You | Muscular Dystrophy Association, (n.d.). https:\/\/www.mda.org\/research\/clinical-trials (accessed July 4, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0815","unstructured":"Duchenne Muscular Dystrophy Clinical Trial - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01874275 (accessed July 4, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0820","unstructured":"Current trials in DMD - TREAT-NMD, (n.d.). https:\/\/treat-nmd.org\/resources-support\/research-overview\/about-clinical-research\/current-trials-in-dmd\/ (accessed July 4, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0825","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.gendis.2019.12.007","article-title":"Promising therapeutic approaches using CRISPR\/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy","volume":"8","author":"Mollanoori","year":"2021","journal-title":"Genes Dis."},{"issue":"11","key":"10.1016\/j.lfs.2023.122003_bb0830","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.ymthe.2021.09.003","article-title":"Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy","volume":"29","author":"Pickar-Oliver","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lfs.2023.122003_bb0835","series-title":"A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)","year":"2023"},{"key":"10.1016\/j.lfs.2023.122003_bb0840","unstructured":"An extension study to evaluate Casimersen or Golodirsen in patients with Duchenne muscular dystrophy - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03532542?term=NCT03532542&draw=2&rank=1 (accessed April 9, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0845","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.lfs.2023.122003_bb0850","unstructured":"Two-part study for dose determination of SRP-5051 (Vesleteplirsen) (Part A), then dose expansion (Part B) in participants with Duchenne muscular dystrophy amenable to exon 51-skipping treatment - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04004065?term=NCT04004065&draw=2&rank=1 (accessed April 9, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0855","unstructured":"Dose-titration and open-label extension study of SRP-4045 in advanced stage Duchenne Muscular Dystrophy (DMD) patients - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02530905?term=NCT02530905&draw=2&rank=1 (accessed April 9, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0860","unstructured":"A 48-week, open label, study to evaluate the efficacy and safety of Casimersen, Eteplirsen and Golodirsen in subjects with Duchenne muscular dystrophy carrying eligible DMD duplications - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04179409?term=NCT04179409&draw=2&rank=1 (accessed April 9, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0865","unstructured":"Study of DS-5141b in patients with Duchenne Muscular Dystrophy - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02667483?term=NCT02667483&draw=2&rank=1 (accessed April 9, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0870","unstructured":"Study to assess the safety and efficacy of viltolarsen in ambulant boys with DMD (RACER53-X) - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04768062?term=NCT04768062&draw=2&rank=1 (accessed April 9, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0875","unstructured":"Study to assess the safety, tolerability, and efficacy of viltolarsen in ambulant and non-ambulant boys with DMD (Galactic53) - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04956289?term=NCT04956289&draw=2&rank=1 (accessed April 9, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0880","unstructured":"Long-term use of viltolarsen in boys with Duchenne Muscular Dystrophy in clinical practice (VILT-502) - full text view - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04687020?term=NCT04687020&draw=2&rank=1 (accessed April 9, 2023)."},{"key":"10.1016\/j.lfs.2023.122003_bb0885","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1007\/s12035-019-01845-w","article-title":"Dystrophin Dp71 and the neuropathophysiology of duchenne muscular dystrophy","volume":"57","author":"Naidoo","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.lfs.2023.122003_bb0890","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jare.2021.07.001","article-title":"CRISPR\/Cas9 gene editing: new hope for Alzheimer's disease therapeutics","volume":"40","author":"Bhardwaj","year":"2022","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.lfs.2023.122003_bb0895","unstructured":"New Gene Editing Strategies Developed for Duchenne Muscular Dystrophy: Newsroom UT Southwestern, Dallas, Texas, (n.d.). https:\/\/www.utsouthwestern.edu\/newsroom\/articles\/year-2021\/duchenne-muscular-dystrophy.html (accessed April 10, 2023)."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523006380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320523006380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:13:38Z","timestamp":1758402818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320523006380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":179,"alternative-id":["S0024320523006380"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122003","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of CRISPR\/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2023.122003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122003"}}